BioSpace News Archive

Reports rapid advancement of COVID-19 antibody programs; combination studies achieve nearly complete neutralization of SARS-CoV-2

NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS ® System for Refractory Epilepsy Funds will also support clinical trial to pursue new indication for the company’s life-changing neuromodulation technology MOUNTAIN VIEW, Calif.--( BUSINESS WIRE )-- NeuroPace, Inc. , a Silicon Valley-based medical technology company, today announced it has raised $67 million in a funding round led by Accelmed Partners with participatio

The world market for in vitro diagnostics (IVD) will reach $83.3 billion in revenues in 2020, according to a recently published report from Kalorama Information, The Worldwide Market for In Vitro Diagnostics . This includes instruments, reagents, kits and equipment-related software and services. Kalorama has just released the 1

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease Designation to MB-207,

Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Board of Directors has unanimously appointed James Graham to the role of Chief Executive Officer.

Vessi Medical, a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY) announced that it secured $1.7 million in funding for its cryoablation solution for superficial bladder cancer.

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting, held August 29 to September 1, 2020.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of two abstracts featuring data from the Phase 3 program evaluating Sci-B-Vac®, the company’s tri-antigenic prophylactic hepatitis B (HBV) vaccine,

Halberd Corporation (OTC PINK:HALB) today announced the signing of a development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments.

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that it will be presenting at the LD 500 Virtual Investor Conference scheduled to take place from September 1-4, 2020.